OrbiMed

Did you know that autosomal dominant polycystic kidney disease, or ADPKD, affects more than 12 million people globally and still lacks truly disease-modifying therapies? Introducing Renasant Bio, a company set out to pioneer a new approach to treating #ADPKD through the development of small molecule correctors and potentiators that target the root cause of the disease. Learn more here: https://lnkd.in/e4GzGekh

It was a great pleasure to host Carl Gordon, Managing Partner at OrbiMed, for a fireside chat on "Insights into Today's Biopharma Landscape" at our annual Catalent Senior Leaders meeting. Carl's candid perspectives on biotech innovation, capital markets, leadership in challenging times, and the ultimate goal of delivering for patients sparked thoughtful dialogue and left us all inspired.

Want to hear from life sciences industry experts discussing topics such as the funding landscape, robotics in the lab, M&A outlook and much more? Then join us at the annual UBS Life Sciences Conference. In our venture capital panel, back for its third iteration, we'll hear from key industry players Amino Collective, EQT Life Sciences, OrbiMed and Versant Ventures to discuss the current landscape and the impacts of AI. Where and when: 5 Broadgate, London, 11 June 2025 13:30 to 17:30 (BST) followed by networking over drinks and a BBQ. Register here: https://from.ubs/6046S9J0u #ShareUBS #LifeSciences #Healthcare #VC #alternatives

Earlier this month, F-Prime, RA Capital Management, and OrbiMed were thrilled to host a Women's Health Symposium. The event was co-organized by Tashy Rodgers, MD and Anastasiya Sybirna, PhD from F-Prime, alongside Hugo Arellano-Santoyo PhD from Raven (RA Ventures), RA Capital's healthcare incubator and Natasha Shervani from OrbiMed.   We welcomed an engaged audience of investors from top-tier VCs and strategics to hear from three fantastic speakers: Dr. Parambir Bhangu shared insights on Organon's commitment to advancing Women’s Health Prof. Linda Griffith (Massachusetts Institute of Technology) introduced her groundbreaking “organ-on-a-chip” disease models Dr. Michael Rogers (Boston Children's Hospital) presented new discoveries from his translational endometriosis mouse model Our roundtable focused on high unmet-need areas such as endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, heavy menstrual bleeding, and female-prevalent conditions like osteoporosis. We discussed the chicken-and-egg problem in the space: a lack of investment leads to limited innovation, yet the complexities of clinical trials and sparse pipelines make it harder to attract investment in the first place. Crucially, we also explored solutions - from novel mechanisms and biomarkers to more translational disease models that can help de-risk programs earlier.   Some of the highlights: Academic funding in women’s health remains heavily skewed toward oncology, leaving non-oncologic gynaecological conditions underfunded and with sparse pipelines. Endometriosis non-invasive diagnostics and biomarkers are a top priority: current surgical confirmation requirements hinder trials, and most lesions are invisible to imaging. Pain, while clinically meaningful in endometriosis, is a noisy and variable endpoint. Validated biomarkers are urgently needed to measure disease modification. There is cautious optimism about the new draft FDA guidance for osteoporosis, which may allow accelerated approval based on improvements in bone mineral density (BMD) rather than fracture reduction. The field is eagerly awaiting the final guidance, particularly regarding safety database and confirmatory study requirements   We are incredibly grateful to our speakers and attendees for a stimulating and solution-focused discussion. Exciting follow-ups are already underway. If you are an entrepreneur or academic working on novel therapeutics, diagnostics, biomarkers, or models for underserved women’s health conditions - we’d love to hear from you! #WomensHealth #BiotechInnovation

Very excited to see this collaboration go live! I am very optimistic that the expertise of ADARx will help bring innovative siRNA-based product candidates to patients with neurological conditions, autoimmune diseases and cancer. Congratulations to Zhen Li and her team, as well as the AbbVie deal team! https://lnkd.in/gJzvifsT.

Today, we announced positive 24-week results from our completed Phase 1/2a trial of PER-001, a first in class endothelin antagonist intravitreal implant for glaucoma, at #ARVO2025. These data support the potential of PER-001 as the first disease-modifying treatment for glaucoma. Learn more here: https://bit.ly/3GK1exC